BLU enhances the effects of anti-angiogenic activity in combination with gemcitabine-based chemotherapeutic agents. [electronic resource]
Producer: 20140114Description: 1236-45 p. digitalISSN:- 1878-5875
- 3-Phosphoinositide-Dependent Protein Kinases -- metabolism
- Antimetabolites, Antineoplastic -- pharmacology
- Apoptosis -- genetics
- Cell Line, Tumor
- Cell Movement
- Cell Proliferation
- Cytoskeletal Proteins
- Deoxycytidine -- analogs & derivatives
- Female
- G1 Phase Cell Cycle Checkpoints
- Human Umbilical Vein Endothelial Cells
- Humans
- Hypoxia-Inducible Factor 1, alpha Subunit -- metabolism
- NF-kappa B -- biosynthesis
- Neovascularization, Pathologic
- Ovarian Neoplasms -- drug therapy
- Phosphorylation -- drug effects
- Proto-Oncogene Proteins c-akt -- metabolism
- TOR Serine-Threonine Kinases -- metabolism
- Tumor Suppressor Protein p53 -- metabolism
- Tumor Suppressor Proteins -- metabolism
- Up-Regulation -- drug effects
- Vascular Endothelial Growth Factor A -- metabolism
- Vascular Endothelial Growth Factor Receptor-2 -- genetics
- bcl-2-Associated X Protein -- biosynthesis
- rho GTP-Binding Proteins -- metabolism
- Gemcitabine
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.